Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Our AI ranks Mckesson Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Mckesson Corp is a large-cap company with a market capitalization of $117.15B. It ranks number 1 by market capitalization among the 7 Wholesale-Drugs, Proprietaries & Druggists' Sundries issuers in our coverage with a current forecast.
For MCK, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -18.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -39.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, MCK included.
Follow MCK free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Wholesale-Drugs, Proprietaries & Druggists' Sundries peers listed below that report each metric.
| Metric | MCK | Rank |
|---|---|---|
| Market Cap | $117.15B | 1/7 |
| P/E Ratio | 26.95x | – |
| Dividend Yield | 0.34% | – |
| EPS | $37.28 | – |
| Revenue/Share | $3525.02 | – |
| FCF/Share | $55.03 | – |
| Metric | MCK | Rank |
|---|---|---|
| ROA | 5.8% | 1/7 |
| ROIC | 36.1% | 1/5 |
| Gross Margin | 3.6% | 6/7 |
| Operating Margin | 1.6% | 2/6 |
| Net Margin | 1.3% | 2/7 |
| EBT Margin | 1.6% | 2/7 |
| Tax Rate | 17.9% | – |
| Metric | MCK | Rank |
|---|---|---|
| Current Ratio | 0.89x | 6/6 |
| Quick Ratio | 0.52x | 6/6 |
| Interest Coverage | 10.1x | 1/6 |
| Working Capital | -$7.52B | 6/6 |
| Metric | MCK | Rank |
|---|---|---|
| Operating Cash Flow | $6.85B | 1/7 |
| Free Cash Flow | $6.42B | 1/5 |
| Capital Spending | -$437M | 4/5 |
| OCF Growth YoY | 4.7% | 4/5 |
| FCF Growth YoY | 1.0% | – |
| FCF/Sales | 1.6% | 2/5 |
| CapEx/Sales | 0.1% | 5/5 |
| Metric | MCK | Rank |
|---|---|---|
| Asset Turnover | 4.65x | 1/5 |
| Receivables Turnover | 13.6x | 4/5 |
| Inventory Turnover | 15.1x | 3/6 |
| Fixed Assets Turnover | 153.1x | 1/5 |
| Days Sales Outstanding | 27 days | 2/5 |
| Days Inventory | 24 days | 4/6 |
| Payables Period | 59 days | 3/5 |
| Cash Conversion Cycle | -8 days | – |
| Metric | MCK | Rank |
|---|---|---|
| Total Revenue | $410.98B | 1/5 |
| Operating Income | $6.50B | 1/6 |
| Net Income | $5.16B | 1/7 |
| SG&A Expense | $8.16B | 1/6 |
| Cost of Goods Sold | $396.03B | 1/7 |
| Metric | MCK | Rank |
|---|---|---|
| Dividends Per Share | $3.37 | – |
| Payout Ratio | 9.0% | – |
| Shares Outstanding | 117M | – |
| Net Income Growth | 28.0% | 3/5 |
| EPS Growth | 49.3% | 1/5 |
| Total Current Assets | $62.84B | 71.1% of assets |
| Cash & Short-term Investments | $5.16B | 5.8% of assets |
| Accounts Receivable | $30.32B | 34.3% of assets |
| Inventory | $26.26B | 29.7% of assets |
| Total Liabilities | $92.19B | |
| Short-term Debt | $6.62B | 7.5% of assets |
Companies classified under the same SEC industry code as Mckesson Corp (Wholesale-Drugs, Proprietaries & Druggists' Sundries): 7 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeShares of McKesson Corp. rose 5.27% to $898.82 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.19% to 7,666.45 and the Dow ...
Option Care Health Inc. OPCH agreed Tuesday to be taken private by Clayton Dubilier & Rice and McKesson Corp. MCK for $32.05 a share in cash. The deal gives the home-infusion provider a total ...
Shares of McKesson Corp. MCK slipped 1.23% to $910.33 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.22% to 7,801.77 ...
Our AI ranks Mckesson Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For MCK, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -18.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -39.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Mckesson Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
7 issuers in our coverage, MCK included, share the SEC industry code Wholesale-Drugs, Proprietaries & Druggists' Sundries. The largest are: Cencora, Inc. (COR), Cardinal Health Inc (CAH), Herbalife Ltd. (HLF), Nu Skin Enterprises, Inc. (NUS), Hwh International Inc. (ESYN), Cosmos Health Inc. (COSM).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.